Sign Up For Free
The world’s largest medicinal cannabis company has urged the government to allow GPs to prescribe the drug, calling on the UK to be a “leader not a laggard” in one of the world’s fastest growing major industries.

Cam Battley, chief corporate officer of Canada-based Aurora Cannabis, said the UK was failing patients who might benefit from medicinal cannabis, as well as forfeiting economic gain, due to the restrictions of the existing regulatory regime.

Sajid Javid, the home secretary, authorized the use of medicinal products derived from cannabis last year following a long-running campaign fronted by the parents of children suffering from severe epilepsy, who reported that cannabis oil helped with their condition.

But it can only be prescribed by specialist physicians and cannot be imported until a prescription has been issued. These rules, coupled with division among doctors about how effective it is, means fewer than 100 patients are thought to have been prescribed it.

“What was the point of creating a medical cannabis system if patients can’t access it?” Battley said, speaking at the annual Cannabis Europa conference in London, attended by leading firms in the nascent but already multibillion dollar industry.

“It’s time for the UK to take this system that is not working and make it work,” he said. “Let’s make sure that general practitioners can prescribe. There’s no need for requiring a specialist consultant to write a prescription. I’d like to see the UK be a leader, not a laggard.”

David Henn, chief executive of Germany-based Cannamedical, backed Battley, saying the law “does not make great sense for patients” and also forced up costs.

He said restrictions on imports caused by the UK’s regulatory regime meant that Cannamedical could profitably sell medicinal cannabis to pharmacies in Germany at $10 (UK) a gram but would have to ask for $30 (UK) a gram to achieve the same margin in the UK.

“We need to be able to hold stock, bring in larger amounts so that as soon as there is a prescription you can distribute to pharmacies,” he said.

He added that a no-deal Brexit could make it near-impossible for UK patients to obtain medicinal cannabis, unless the UK aligns itself with EU rules on good manufacturing practice.

Campaigners and companies that produce cannabis say patients have reported that it can help with pain, epilepsy, and nausea, including sickness caused by chemotherapy.

Battley told The Guardian that the company was “making progress” in discussions with the government about loosening regulation, adding that it was only in the last year that politicians had been willing to speak to the company.

He pointed to Aurora’s domestic market of Canada, where he said the number of patients had gone from a handful to 400,000 in just a few years, with 20,000 physicians having prescribed cannabis since its medical use was legalized in 2001.

Recreational cannabis is also legal in Canada, which has become the de facto centre of the global industry, hosting giants such as Aurora, which produces 160,000kg of dried flower a year and has a stock market value of more than $5.5 billion (UK).

Source: https://www.theguardian.com/society/2019/jun/24/medical-cannabis-firms-press-uk-to-loosen-prescription-rules

This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.


Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.